MX2019005202A - Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos. - Google Patents

Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.

Info

Publication number
MX2019005202A
MX2019005202A MX2019005202A MX2019005202A MX2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A
Authority
MX
Mexico
Prior art keywords
capsaicin
injectable
injectable formulations
stable aqueous
same
Prior art date
Application number
MX2019005202A
Other languages
English (en)
Spanish (es)
Inventor
Ostovic Drazen
Fred Musso Gary
Original Assignee
Centrexion Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrexion Therapeutics Corp filed Critical Centrexion Therapeutics Corp
Publication of MX2019005202A publication Critical patent/MX2019005202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019005202A 2016-11-02 2017-11-02 Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos. MX2019005202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416345P 2016-11-02 2016-11-02
PCT/US2017/059628 WO2018085476A1 (en) 2016-11-02 2017-11-02 Stable aqueous capsaicin injectable formulations and medical uses thereof

Publications (1)

Publication Number Publication Date
MX2019005202A true MX2019005202A (es) 2019-10-14

Family

ID=62077165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005202A MX2019005202A (es) 2016-11-02 2017-11-02 Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.

Country Status (12)

Country Link
US (7) US11000490B2 (enExample)
EP (1) EP3534961B1 (enExample)
JP (1) JP7100635B2 (enExample)
KR (1) KR102657458B1 (enExample)
CN (1) CN110035740B (enExample)
AU (1) AU2017353782B2 (enExample)
CA (1) CA3041121A1 (enExample)
ES (1) ES3066533T3 (enExample)
IL (1) IL266279B2 (enExample)
MX (1) MX2019005202A (enExample)
NZ (1) NZ752750A (enExample)
WO (1) WO2018085476A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
MX2021013934A (es) 2020-04-05 2021-12-15 Pfizer Compuestos y metodos para el tratamiento de covid-19.
CN113855626B (zh) * 2020-08-07 2023-03-24 北京泰德制药股份有限公司 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法
TR2021013305A2 (tr) * 2021-08-23 2023-03-21 Tuem Ekip Ilac Anonim Sirketi Li̇yofi̇li̇ze levosi̇mendan formülasyonlari

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
DE59408028D1 (de) 1993-09-30 1999-05-06 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
EP1201241B8 (en) 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
JP2002514221A (ja) 1997-05-27 2002-05-14 アルゴス ファーマシューティカル コーポレーション カプサイシノイド及びその強化薬を含有する鎮痛薬組成物
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
WO2004009064A1 (de) 2002-07-19 2004-01-29 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
WO2004056305A2 (en) 2002-12-18 2004-07-08 Algorx Administration of capsaicinoids
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
WO2006066419A1 (de) 2004-12-22 2006-06-29 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
EP1838301B1 (de) 2004-12-28 2015-01-28 Mestex AG Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen
ES2384244T3 (es) 2004-12-28 2012-07-02 Mestex Ag Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8222564B2 (en) 2008-02-13 2012-07-17 Tyco Healthcare Group, Lp Methods of altering surgical fiber
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
WO2012134943A1 (en) 2011-03-25 2012-10-04 Abbott Laboratories Trpv1 antagonists
KR101769010B1 (ko) 2011-09-09 2017-08-17 비쭈리 헬스 사이언스 엘엘씨 Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
EP2838536B1 (en) 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US20150190509A1 (en) 2012-08-03 2015-07-09 Mestex Ag Resiniferatoxin solution
US20140142073A1 (en) * 2012-11-12 2014-05-22 Api Genesis, Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US11351139B2 (en) * 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
ES2838756T3 (es) 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
MX2016013486A (es) 2014-04-14 2017-05-10 Flex Pharma Inc Activadores de canales ionicos y metodos de uso.
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
EP3182968A4 (en) 2014-08-19 2018-05-09 Muzari, Mandishora Israel Capsaicinoids and uses thereof as medicaments
US20180311189A1 (en) 2014-11-13 2018-11-01 Centrexion Therapeutics Corporation Capsaicinoids for Use in Treating ACRAL Lick Granuloma
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US20180021286A1 (en) 2015-02-02 2018-01-25 Enspire Group LLC Stabilized dialkyl fumarate compositions
CA2987517A1 (en) 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
US20200261409A1 (en) 2015-11-20 2020-08-20 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
US9989978B2 (en) 2016-01-21 2018-06-05 Itt Manufacturing Enterprises Llc Natural gas pressure regulator having adjustable valve seat
US20190022036A1 (en) 2016-01-22 2019-01-24 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of morton's neuroma pain
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3025268A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia

Also Published As

Publication number Publication date
US20220211649A1 (en) 2022-07-07
US10765649B2 (en) 2020-09-08
NZ752750A (en) 2023-05-26
EP3534961A4 (en) 2020-05-27
RU2019116788A (ru) 2020-12-03
US20200046656A1 (en) 2020-02-13
EP3534961C0 (en) 2026-02-11
AU2017353782B2 (en) 2022-06-02
US20200093765A1 (en) 2020-03-26
CN110035740A (zh) 2019-07-19
US20190254996A1 (en) 2019-08-22
WO2018085476A1 (en) 2018-05-11
RU2019116788A3 (enExample) 2021-02-25
KR20190101368A (ko) 2019-08-30
US20210052522A1 (en) 2021-02-25
CN110035740B (zh) 2023-08-04
US20240423931A1 (en) 2024-12-26
JP2019537589A (ja) 2019-12-26
KR102657458B1 (ko) 2024-04-12
US10772853B2 (en) 2020-09-15
US11344516B2 (en) 2022-05-31
EP3534961A1 (en) 2019-09-11
US11992470B2 (en) 2024-05-28
US20200093766A1 (en) 2020-03-26
IL266279B1 (en) 2023-03-01
JP7100635B2 (ja) 2022-07-13
US11000490B2 (en) 2021-05-11
IL266279B2 (en) 2023-07-01
AU2017353782A1 (en) 2019-05-16
EP3534961B1 (en) 2026-02-11
ES3066533T3 (en) 2026-05-13
US10493047B2 (en) 2019-12-03
CA3041121A1 (en) 2018-05-11
BR112019008239A2 (pt) 2019-07-16
IL266279A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
CO2023010562A2 (es) Degradadores irak4 y usos de los mismos
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
NZ752750A (en) Stable aqueous capsaicin injectable formulations and medical uses thereof
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
CU20190005A7 (es) Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico
MX2016001621A (es) Dispositivos y metodos de unidades multiples para administracion de farmacos.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
UY35988A (es) Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
AR106364A1 (es) Derivados de insulina y sus usos médicos
MX394318B (es) Inhibidores pirazolicos de magl
MX2015005879A (es) Formulaciones de capsaicinoides basadas en agua, y tratamiento en combinacion con un corticosteroide.
CL2017001024A1 (es) Formulación de buprenorfina inyectable
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CO2025007764A2 (es) Degradadores de irak4 y usos de los mismos
BR112016027435A2 (pt) formulação inovadora de meloxicam
MX2009013183A (es) Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso.